Related Experiment Video
Updated: Jan 14, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
The discovery of Bevacizumab. An historical reappraisal
1Department of Translational Biomedicine and Neuroscience, University of Bari, Bari, Italy. domenico.ribatti@uniba.it.
In 1997, the monoclonal antibody A4.6.1 was humanized to create Bevacizumab (Avastin, Genentech), an antibody suitable for clinical trials. In February 2004, Bevacizumab was approved in a randomized double-blind phase III study in which was administered in combination with bolus IFL (irinotecan, 5FU, leucovorin) chemotherapy as first-line therapy for previous untreated metastatic colorectal cancer. In 2020, the EMA approved the first biosimilar of Bevacizumab for the treatment of multiple types of cancer. The administration of Bevacizumab became popular among ophthalmologists for different ocular diseases. However, in most cases of cancers, including breast, melanoma, pancreatic and prostate cancer, Bevacizumab failed to increase survival. Despite impressive performances in animal models, however, inhibitors are not performing nearly as well in humans. The limitations of applying Bevacizumab are attributed to drug resistance, metastasis promotion and reduced delivery of chemotherapeutic agents, resulting from the dramatic decrease in tumor vasculature.
In 1997, the monoclonal antibody A4.6.1 was humanized to create Bevacizumab (Avastin, Genentech), an antibody suitable for clinical trials. In February 2004, Bevacizumab was approved in a randomized double-blind phase III study in which was administered in combination with bolus IFL (irinotecan, 5FU, leucovorin) chemotherapy as first-line therapy for previous untreated metastatic colorectal cancer. In 2020, the EMA approved the first biosimilar of Bevacizumab for the treatment of multiple types of cancer. The administration of Bevacizumab became popular among ophthalmologists for different ocular diseases. However, in most cases of cancers, including breast, melanoma, pancreatic and prostate cancer, Bevacizumab failed to increase survival. Despite impressive performances in animal models, however, inhibitors are not performing nearly as well in humans. The limitations of applying Bevacizumab are attributed to drug resistance, metastasis promotion and reduced delivery of chemotherapeutic agents, resulting from the dramatic decrease in tumor vasculature.
More Related Videos
Related Concept Videos
01:13Bioequivalence studies: Biowaivers
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...